Alliance for Multispecialty Research (AMR) announced on December 15 that it entered into an agreement to acquire Affinity Health.
Founded in 2015, Affinity Health provides clinical research delivery with exceptional patient care and safety.
AMR is a leading independent site management company with a 30-year history of successfully executing clinical trials across a network of 32 clinical sites. It has more than 130 dedicated principal investigators across upwards of 20 therapeutic areas, providing its pharmaceutical sponsor and contract research organization clients access to patients. Since 2022, the company has been owned by Curewell Capital, a private equity group based out of Los Angeles.
This acquisition increases AMR’s regional footprint and is another milestone in its goals around scalability and growth. This is also AMR’s first acquisition of 2023. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the 41st clinical trials transaction of the year.
